Italia markets closed

MDxHealth SA (0O8G.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,9857+2,7057 (+966,32%)
Alla chiusura: 04:57PM GMT
Schermo intero
Chiusura precedente0,2800
Aperto2,9857
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,9857 - 2,9857
Intervallo di 52 settimane1,9750 - 6,8000
Volume85
Media Volume1.757
Capitalizzazione1,651M
Beta (5 anni mensile)0,73
Rapporto PE (ttm)N/D
EPS (ttm)-0,2150
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    MDxHealth Reports Preliminary Q3-2023 Revenues

    NEWS RELEASE – INSIDE AND REGULATED INFORMATION9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today reported preliminary third quarter 2023 revenues, units, and cash position. For the third quarter ended September 30, 2023, the Company expects to report revenues of approximately $19.3 million, representing an increase of 7

  • GlobeNewswire

    MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting

    NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONOCTOBER 2, 2023, 4:00pm ET / 22:00 CET MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting IRVINE, CA, and HERSTAL, BELGIUM – October 2, 2023 – MDxHealth SA (NASDAQ/Euronext Brussels: MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announces a proposed transition from a dual listing of the Company's American Depos

  • GlobeNewswire

    Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer

    NEWS RELEASE September 26, 2023, 5:00PM EDT / 23:00 CET Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer IRVINE, CA, and HERSTAL, BELGIUM – September 26, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the University of Oxford to investigate the correlation